FDA Approval Alert: The Need-to-Know | Tislelizumab/Chemotherapy in Gastric/GEJ Adenocarcinoma

In December 2024, the FDA approved first-line tislelizumab-jsgr plus fluoropyrimidine- and platinum-based chemotherapy for patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma with PD-L1 tumor expression.

Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma
Article
Dec 27, 2024 1:38 PM
Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.